![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 6 of 6. This is the beginning of the thread.
Posted by Lamdage22 on September 30, 2014, at 10:59:52
http://www.bluelight.org/vb/threads/721283-New-medications-and-breakthroughs!
That pretty much sums it up.
Posted by Hugh on September 30, 2014, at 15:06:48
In reply to New drug developments, posted by Lamdage22 on September 30, 2014, at 10:59:52
That's an impressive list. It might be the most comprehensive one I've seen. I can add one more experimental treatment -- lasers.
Posted by Lamdage22 on October 1, 2014, at 12:52:47
In reply to Re: New drug developments, posted by Hugh on September 30, 2014, at 15:06:48
Thanks, yeah i thought so, too.
Neurogenesis seems to be the next big thing. Bigger than serotonin. The only thing i miss are Anandamide based Schizophrenia treatments which might be even more important for me personally.
I am grateful for the antipsychotics we have, but the side effects are not pretty.
Anandamide seems to be further in the future than neurogenesis. There is cannabidiol, but with unknown or problematic long term effects such as immune system shutdown.
Posted by Lamdage22 on October 1, 2014, at 12:58:25
In reply to Re: New drug developments, posted by Lamdage22 on October 1, 2014, at 12:52:47
Anandamide: http://www.ncbi.nlm.nih.gov/m/pubmed/15354183/
Inversly correlated with psychotic symptoms. It could be natures attempt to cure psychosis.
Posted by Lamdage22 on October 2, 2014, at 13:53:12
In reply to Re: New drug developments, posted by Lamdage22 on October 1, 2014, at 12:58:25
I received this email from Naurex:
Julian
Thank you for your interest. Naurexs human clinical studies are currently focused in the area of depression. We believe the drugs in our research and development pipeline have high potential as therapies for other diseases as well. We are currently conducting early-stage research of our compounds across a number of psychiatric and neurologic conditions. We hope to begin human clinical studies in these areas in the near future. Please continue to check clinicaltrials.gov
http://clinicaltrials.gov/ct2/results?term=Naurex&Search=Search
as well as the Naurex website
www.naurex.com
for more information on ongoing clinical trials.
Best regards,
Naurex Inc.
From: Julian **********
Sent: Sunday, September 21, 2014 7:11 AM
To: Naurex Corporate
Subject: Glyx-13 open label schizophrenia/schizo-affective
Name: Julian *******
E-Mail: **************
Subject: Glyx-13 open label schizophrenia/schizo-affectiveMessage: Can you notify me if you conduct an open label study for schizo-affective or schizophrenic patients with Glyx-13?
Is anything like this planned?
Thank you,
JulianSo we have those links to watch:
http://clinicaltrials.gov/ct2/results?term=Naurex&Search=Search
http://clinicaltrials.gov/ct2/results?term=glyx-13&Search=Search
http://clinicaltrials.gov/ct2/results?term=nrx-1074&Search=Searchwww.naurex.com
One of those studies, funded by Northwestern University, that is currently recruiting is for schizophrenics and schizo-affective patients. I hope it will come out with a statement as to wether or not these two compounds can be utilized in schizoid-disorders without a too big risk (or maybe without any risk at all?) of causing psychosis. Unfortunately MAO Inhibitors are poison for people prone to psychosis.
Literally, even if they are, along with Remeron, to my mind the only antidepressants that could improve depression and negative symptoms in most of these patients. This is very unfortunate. And with the introduction of Naurex´s two lead compounds, we just may have much better news for people who are both depressed and prone to psychosis and/or affected by negative schizophrenia symptoms + the inherent propensity toward psychosis.
Speaking of psychosis, Anandamide based treatments are much further away unfortunately.
But even they will eventually come. I hope that research will start off soon and we can watch it coming closer and closer to us, the patients, just like Glyx-13 and NRX1074.
So the bottom line is: Hang in there!
Posted by Hugh on October 6, 2014, at 14:15:20
In reply to New drug developments, posted by Lamdage22 on September 30, 2014, at 10:59:52
"In this minireview, we briefly summarize major themes in current approaches to understanding mood disorders focusing on molecular views of depression and antidepressant action."
Complete article:
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.